Recent News

• 11.19.2025 - Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025
• 11.19.2025 - Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call
• 10.01.2025 - Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device
• 09.18.2025 - Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
• 08.20.2025 - Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Recent Filings

• 11.19.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.19.2025 - 8-K Current report
• 11.19.2025 - EX-99.1 EX-99.1
• 11.14.2025 - NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
• 11.04.2025 - 8-K Current report
• 10.24.2025 - 8-K Current report
• 10.24.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 09.29.2025 - DEF 14A Other definitive proxy statements
• 09.18.2025 - EX-99.1 EX-99.1
• 09.18.2025 - 8-K Current report